ArticleJSES international2024
Treating pathological metastatic fractures of the humerus by compound osteosynthesis: a retrospective cohort study.
Article in JSES international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [Resection of a chondrosarcoma of the first metacarpal and reconstruction using composite osteosynthesis : Case report and literature review].Unfallchirurgie (Heidelberg, Germany) · 2026Article
- Which Factors Affect Functional Outcomes and Survival in Metastatic Humeral Fractures Treated With Nails?Orthopaedic surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The number of malignant tumors is increasing as are bone metastases, such as those in the humerus. Arm function is important for an independent everyday life. In this study, compound osteosynthesis of metastatic fractures of the humerus is examined for its suitability in light of the competing risk of death. Methods: This retrospective monocentric study includes a cohort of tumor patients who underwent primary compound osteosynthesis for pathological humeral fractures. The main endpoint was the continued existence of compound osteosynthesis using competing risk analysis to contrast failure and death. Failure was defined as mechanical failure of the osteosynthesis construct like refracture or plate-and-screw dislocation or loosening, which provides an indication for reintervention. Other complications are also described. Results: We included 36 consecutive patients (64% male, mean age: 71.6 yr) from September 2007 to October 2020. In 58% of the cases, the left humerus was fractured. Lung carcinoma was the most common cause of bone metastases (27.8%). Compound osteosynthesis was performed with a median delay of 5 days after diagnosis of the pathologic fracture. Postoperative complications occurred in 7 of the 36 patients (19.4%): radial nerve palsy (n = 3), postoperative hematoma (n = 2), refracture (n = 2), and screw loosening (n = 1). Few mechanical failures (8.3%) occurred within the first year; only 1 patient needed revision of the osteosynthesis (2.8%). Median patient survival after compound osteosynthesis was 26.6 weeks. Competing risk analysis showed that for up to 2 years, the risk of death is clearly dominant over the risk of osteosynthesis failure from surgery. Conclusion: Our study shows that compound osteosynthesis of the humerus is a suitable option for patients with pathologic humerus fractures. Compound osteosynthesis of the humerus usually survives the duration of malignant tumor disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.